KUHNIL PHARM

Kuhnil Pharm

March 2023

FORWARD – LOOKING STATEMENTS

KUHNIL PHARM. CO., LTD.

This presentation may contain forward-looking statements based on current assumptions and forecasts made by Kuhnil group or subgroup management.

Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

These factors include those discussed in Kuhnil group's public reports which are available on the *Kuhnil* website at www.kuhnil.com and *Penmix* at www.penmix.com.

The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

About Kuhnil

History

KUHNIL PHARM. CO., LTD.

1969

Kuhnil Pharm established

1990

KGMP plant approved

1992

R&D center established

2000

Penmix Ltd established

2004

License agreement with BASF for Omacor®

2009

Ohsong Pharm established

2012

License agreement with Neurim for Circadin®

2016

License agreement with Neurim for Slenyto®

2017

2nd New Factory Foundation

2017

ROSUMEGA® launched in KR

2019

EU GMP approval

2020

ROSUMEGA® MA approved in EU

2021

Kuhnil Biopharm established

2022

ATOMEGA® launched in KR

KUHNIL GROUP

KUHNIL PHARM. CO., LTD.

KUHNIL PHARM. CO. LTD.

Prescription Drug-Oriented Pharmaceutical Company
(Fully-integrated pharma company)

PENMIX LTD.

CMO Specialized Company
(Penicillin / Injection Formulation)

KUHNIL BIOPHARM CO. LTD.

Generics CSO business Company

OHSONG PHARM CO. LTD.

Import / Export of
Pharmaceutical Finished goods and APIs

KUHNIL PHARM

KUHNIL PHARM. CO., LTD.

Overview

Established	1969
C.E.O.	Han Kuk Lee
Headquarter	Seoul, Korea
R&D Center	Seoul, Korea
Manufacturing Site	Cheonan, Korea
Sales	106M USD (2022)
No. of Employees	363 (2022)

Annual Sales



[Unit : USD]

GLOBAL PARTNERSHIP

KUHNIL PHARM. CO., LTD.

Cardiovascular	BASF We create chemistry, Daiichi-Sankyo, SIEGFRIED RHEIN, OEP
Central Neural System	Neurim PHARMACEUTICALS
Gastroenterology	BIOCODEX
Others	Wyeth, lek a Sandoz company, biosyntech, TTY BIOPHARM, FERRING PHARMACEUTICALS

More than **50** years!

with **30** global partner companies!

KUHNIL FACTORY

KUHNIL PHARM. CO., LTD.

❖ QUALITY ASSURED PHARMACEUTICAL, COMPLIANT WITH EU GMP

GMP STATUS

KGMP approved (since 1990)

↘ **Solid Dosage Forms** Tablet, Hard capsule, Soft capsule, Dry syrup, Powder, Micro granule
↘ **Inhalations** Solution, Suspension …

EUGMP approved (since 2019)

SCALE

↘ **Kuhnil 1st Factory** Building Area: 3,127 ㎡
↘ **Kuhnil 2nd Factory** Building Area: 6,365 ㎡

Kuhnil is seeking out-licensing opportunities for global commercialization of our assets

ROSUMEGA® (FDC of rosuvastatin + omega-3), Omacor® mini capsules
Deferasirox powder, Tadalafil micro-granules, Desmopressin micro-granules

PRODUCT PROFILE

ROSUMEGA®

KUHNIL PHARM. CO., LTD.

FIRST IN CLASS: FDC of '-STATIN+OMEGA-3'

"Optimum combination for hyperlipidemia with high TG and LDL-C"

- **Rosuvastatin calcium 5mg**
- **Omega-3 acid ethylesters 90 1000mg**
  (EPA ethylester 460mg + DHA ethylester 380mg)

- **Mixed Hyperlipidemia**

- **Once daily, 2~4 soft capsules per day**

❖ KEY MESSAGE

✓ **Dual Effect** to reduce LCL-C and TG Level by patented technology* (3-layer coating)

✓ **Combo's additional** decrease effect in residual cardiovascular risk
& Omega-3's **multiple** effects (Lowering blood pressure, reducing fatty liver, antiarrhythmic effect)

* KR10-1335365B1 (Expiration date: 2033.05.21)

OMACOR® MINI CAPSULES

KUHNIL PHARM. CO., LTD.

SEAMLESS MINI CAPSULES:

"Improved Patient Adherence & ease of administration of Omega-3"

- **Omega-3 acid ethylesters 90 2g**
  (EPA ethylester 460mg + DHA ethylester 380mg)
- **Hypertriglyceridemia; Hyperlipidemia**
- **Once daily, 2g or up to 4g if necessary**

❖ KEY MESSAGE

✓ **Ideal package** for administration of ESC recommended strength of Omega-3
(ESC: European Society of Cardiology)

✓ **Easy to swallow, patient-friendly** dosage form

EXFFERIDE® POWDER

KUHNIL PHARM. CO., LTD.

The IMD of Exjade® (Novartis, Iron Chelator)

"Improvement in patient convenience"

- Deferasirox 125, 250, 500, 1000 mg
- Chronic iron overload due to blood transfusions
- Once daily; in fasting state

❖ KEY MESSAGE

✓ **Easier administration** of powder formulation compared to the original's dispersible tablet

✓ **Wider range of dosage strength**

*KR-1695970 (Expiration date: 2035.07.31)

DESMOPRESSIN OD!FS

KUHNIL PHARM. CO., LTD.

Oral Dissolving in a Few Seconds

"Unique formulation technology to enable instant dissolving without water "

- **Desmopressin 0.1mg, 0.2mg**
- **Nocturnal enuresis**
- **Once daily; 0.1 or up to 0.4mg before bedtime**

❖ KEY MESSAGE

- ✓ **No water needed** and relieves stress taking medicine before bedtime
- ✓ **No residual feeling after administration** & Sweet taste

TADALAFIL OD!FS

KUHNIL PHARM. CO., LTD.

Oral Dissolving in a Few Seconds

"Unique formulation technology to enable instant dissolving without water "

- Tadalafil 5mg, 10mg, 20mg
- Erectile dysfunction
- Once Daily; before sexual activity

❖ KEY MESSAGE

- ✓ **Improved privacy** with extra-thin sachet
- ✓ **No water needed** & No residual feeling

R&D PIPELINES

R&D Pipelines

KUHNIL PHARM. CO., LTD.

❖ Soft/Mini Capsule

		2023				2024				2025				2026				2027				2028				2029				2030 ~
		1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
Rosuvastatin+Omega-3 (High strength)	Dyslipidemia	PV				BE				NDA				Launch																
Atorvastatin+Omega-3	Dyslipidemia	PV								BE				NDA				Launch												
Pitavastatin+Omega-3	Dyslipidemia	PV								BE								NDA				Launch								
Cyclosporine mini-capsule	Immunosuppressant	PV								BE								NDA								Launch				

❖ Generic

		2023				2024				2025				2026				2027				2028				2029				2030 ~
		1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
97% EPA (Vascepa)	Dyslipidemia	PV								NDA								Launch												
Lubiprostone	Constipation	PV				BE				NDA								Launch												
Nilotinib	Acute myeloid leukemia	Formulation								PV								BE				NDA				Launch				
Abemaciclib	Breast cancer	Formulation								PV								BE				NDA				Launch				
Gilteritinib	Acute myeloid leukemia	For								PV								BE								NDA				Launch
Sucroferric oxyhydroxide	Hyperphosphatemia	Formulation				PV				BE								NDA												Launch

R&D Pipelines

KUHNIL PHARM. CO., LTD.

❖ Highly Potent Drug

		2023				2024				2025				2026				2027				2028				2029				2030 ~
		1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
Axitinib	Renal cell carcinoma	PV		BE			NDA							Launch																
Tofacitinib	Rheumatoid arthritis	PV							BE		NDA					Launch														
Olaparib	Pancreas cancer	Formulation								PV					BE					NDA				Launch						
Nilotinib	Acute myeloid leukemia	Formulation								PV							BE						NDA			Launch				
Palbociclib	Breast cancer	PV				BE					NDA								Launch											
Regorafenib	Colon carcinoma	PV				BE		NDA						Launch																
Dasatinib	Leukemia	PV								BE		NDA			Launch															
Midostaurin	Acute myeloid leukemia	PV												BE		NDA					Launch									

❖ High purity raw material

		2023				2024				2025				2026				2027				2028				2029				2030 ~
		1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
97% EPA	Dyslipidemia	PV										NDA				Launch														
DSPC	For preparation of lipid nano-particle (LNP)	PV											NDA			Launch														

OH, KUHNIL

THANK YOU

www.kuhnil.com

For further information please contact:

Business Development Team
k5300@kuhnil.com

KUHNIL PHARM. CO., LTD.